Jakafi and Garlic drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Jakafi (ruxolitinib phosphate) and Garlic (allium sativum). Common drug interactions include chills among females and anaemia among males.
The phase IV clinical study analyzes what interactions people have when they take Jakafi and Garlic. It is created by eHealthMe based on reports of 41 people who take the same drugs from the FDA, and is updated regularly.
What is Jakafi?
Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.
What is Garlic?
Garlic has active ingredients of allium sativum. It is often used in heart health. eHealthMe is studying from 2,714 Garlic users. Check the latest studies of Garlic.
41 people who take Jakafi and Garlic together, and have interactions are studied.
What are the common drug interactions of Jakafi and Garlic, by gender? *:
female:
- Chills (felling of cold)
- Pyrexia (fever)
- Syncope (loss of consciousness with an inability to maintain postural tone)
- Stomatitis (inflammation of mucous membrane of mouth)
male:
- Anaemia (lack of blood)
- Disease progression
- Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
- Splenomegaly (enlargement of spleen)
What are the common drug interactions of Jakafi and Garlic, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Anaemia (lack of blood)
- Chills (felling of cold)
- Disease progression
- Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
- Pyrexia (fever)
- Splenomegaly (enlargement of spleen)
- Syncope (loss of consciousness with an inability to maintain postural tone)
What are the existing conditions these people have? *
- Splenomegaly (enlargement of spleen): 6 people, 14.63%
- Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 5 people, 12.20%
- Essential Thrombocythaemia (chronic blood cancer): 4 people, 9.76%
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 7.32%
- Anaemia (lack of blood): 3 people, 7.32%
* Approximation only. Some reports may have incomplete information.
Do you take Jakafi and Garlic?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Jakafi and Garlic:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Jakafi:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Garlic:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Jakafi and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Garlic and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on ruxolitinib phosphate and allium sativum (the active ingredients of Jakafi and Garlic, respectively), and Jakafi and Garlic (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Tenormin cause Hypotension? - 2 seconds ago
- Could Lorazepam cause Confusion? - 2 seconds ago
- Carotid Artery Stenosis and Appetite Decreased - 23 seconds ago
- Carotid Artery Stenosis and Appetite - Decreased - 24 seconds ago
- Rickets and Crohn'S Disease - 40 seconds ago
- Drug interactions of Methocarbamol and Dulera - 50 seconds ago
- Chronic Obstructive Pulmonary Disease and Drug Withdrawal Syndrome - a minute ago
- Could Tegretol cause Fluid Retention? - a minute ago
- Drug interactions of Alendronic Acid and Calcitriol - a minute ago
- Could Bupropion Hydrochloride cause Skin - Clammy? - a minute ago